Entity

Time filter

Source Type

Genoa, Italy

The University of Genoa is one of the largest universities in Italy. Located in Liguria on the Italian Riviera, the university was founded in 1481. It currently has about 40,000 students, 1,800 teaching and research staff and about 1,580 administrative staff. Wikipedia.


Patent
University of Genoa and S Sistemi S.A.S. | Date: 2014-02-02

A method for destroying asbestos in mainly organic matrix asbestos-containing waste includes the steps of: preparing the asbestos-containing waste; preparing a supercritical aqueous phase; letting the asbestos and the primarily organic matrix of the asbestos-containing waste react with the aqueous phase for a time t in an appropriate reactor at a predetermined pressure P and temperature T to maintain the aqueous phase in supercritical condition; cooling and condensing the aqueous phase flowing out of the reactor; and separating the aqueous phase from any entrained solid products therein. The step of preparing the supercritical aqueous phase includes an additional step, in which an oxidizing compound is added in a predetermined concentration Cl, the pressure P is in a range from 25 to 27 MPa, and the temperature T is in a range from 600 C. to 650 C., causing the asbestos and the organic binder to be simultaneously destroyed.


A scientific review informed about the characteristics of basic compounds and materials used in industrial and technological chemistry. The review emphasized on the the properties of liquid bases, the characterization, and use of solid bases. The contribution was intended to emphasize the linkage between the chemical knowledge of acid-base interactions and the engineering of chemical processes, along with their environmental impact. It also provided evidence of trends aimed at improving process safety and limiting environmental pollution when they were related to the increased use of solid basic materials. Source


Patent
Novo Nordisk AS, Innate Pharma and University of Genoa | Date: 2015-03-16

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.


Patent
Novo Nordisk AS, Innate Pharma and University of Genoa | Date: 2015-08-18

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.


Patent
Novo Nordisk AS, University of Genoa and Bristol Myers Squibb | Date: 2013-12-13

The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

Discover hidden collaborations